全球 VISTA 抑制剂市场：临床试验和市场机会洞察 (2024)

Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2024

出版日期: 2024年06月01日 | 出版商:

KuicK Research | 英文 96 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

随着研究和开发领域的发展、技术的进步和研究人员知识库的增加，人们发现许多蛋白质在许多疾病的发生和进展中发挥核心作用。其中，免疫检查点蛋白因其在抑制抗癌免疫反应中发挥作用而引起人们的关注，并已成为一个有希望的治疗标靶。 VISTA 蛋白是最新发现的检查点蛋白之一，具有区别于其他检查点蛋白的特殊特性，并显示出治疗癌症和发炎性疾病的潜力。因此，VISTA 已成为多项研究的主题，製药公司正在透过开发针对 VISTA 的药物来补充这些努力。

T 细胞活化的 V 结构域 Ig 抑制因子，通常称为 VISTA，是一种免疫检查点蛋白，对免疫系统发挥抑制和刺激作用。已知的其他免疫检查点仅能负向调节免疫反应，而后者正是 VISTA 的独特之处。抑制 VISTA 的抑制功能已成为癌症治疗的显着方法，而 VISTA 的免疫系统刺激功能已在小鼠模型中得到广泛研究。

根据这些研究，製药和生技公司正在专注于开发 VISTA 的治疗介入措施，主要用于癌症治疗。然而，该领域并非没有课题，许多课题已退出临床开发。然而，新一代 VISTA 抑制剂正在开发中，以解决这些候选药物的缺点。

本报告调查了全球 VISTA 抑制剂市场，并提供了市场概况，包括药物趋势、临床试验趋势、区域趋势以及进入市场的公司竞争格局。

Global VISTA Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
VISTA Inhibitors Clinical Trials: 8 Drugs
US Dominating VISTA Inhibitors Clinical Trials Landscape: 5 Drugs
Global VISTA Inhibitors Market Trends & Clinical Innovation
Competitive Landscape: Insight On 10 Companies
Future Clinical & Commercialization Opportunities

With evolution in the research and development domain, along with technological advancements and the increasing knowledge bank of researchers, a number of proteins have been discovered to play central roles in development and progression of many diseases. Among these, immune checkpoint proteins have especially gained attention for their role in suppressing anti-cancer immune responses and have emerged as promising therapeutic targets. The VISTA protein is one of the newest checkpoint proteins to be discovered, which has showed potential in treating both cancer and inflammatory diseases because of its extraordinary properties that make it different from its fellow checkpoint proteins. As a result, it has become the subject of several research studies, with pharmaceutical companies complementing these efforts with the development of drugs targeting VISTA.

V-domain Ig suppressor of T cell activation, commonly known as VISTA, is an immune checkpoint protein which exerts both inhibitory and stimulatory effects on the immune system. Other identified immune checkpoints are only known to negatively regulate immune responses, which is why the latter makes VISTA unique. Blocking its inhibitory functions has emerged as a hot approach in the treatment of cancer, while its immune system stimulatory functions have been explored widely in murine models.

With these research studies serving as the foundation, several pharmaceutical and biotechnology companies have been focusing on the development of therapeutic interventions that target the VISTA, mainly for the management of cancer, given that most clinical studies were conducted to elucidate its role in cancer. However, the field has not been without challenges, with many candidates being withdrawn from clinical development. However, new generation VISTA inhibitors are being developed to address the shortcomings of these candidates.

CA-170, developed by Aurigene Oncology and Curis, marks a significant advancement in the landscape of VISTA-targeted therapies. CA-170 is a first-in-class oral small molecule that directly targets both PD-1/PD-L1 and VISTA pathways. It is currently undergoing phase 2/3 clinical trials in India for the management of non-squamous non-small cell lung cancer, making it the candidate farthest ahead in the pipeline of VISTA-targeted therapies. While CA-170 has shown anti-tumor activity in multiple preclinical models, results from these ongoing clinical trials are yet to be revealed by Aurigene or Curis.

In addition to Aurigene and Curis, several research institutes, and biotechnology and pharmaceutical companies are actively pursuing VISTA inhibitors; these include Cancer Prevention and Research Institute of Texas, Kineta, Sensei Biotherapeutics, Washington University among others. Therefore, the current market for VISTA targeted therapies is witnessing a high level of competition and innovation, albeit with smaller companies dominating and larger companies waiting for breakthroughs before making their way into the market.

At present, cancer, mainly solid tumors, are dominating the research and development landscape of VISTA-targeted therapies. However, ongoing research has also associated the functions of VISTA with autoimmune and inflammatory disorders, wherein aberrant immune system activation damages tissue. This can however, with averted with the use of VISTA agonists, which can help expand the potential of VISTA as a therapeutic target to diseases mediated by the immune system. Additionally, modulation of VISTA activity has also been linked to viral infection through research findings indicating the VISTA plays a role in regulating the immune responses in viral infections. Therefore, as research findings continue linking VISTA functions to new indications, it becomes increasingly evident that researchers are yet to unravel the complexities of VISTA.

In conclusion, the landscape of VISTA-targeted therapeutics is characterized by active research, early-stage clinical development, and growing interest from both the scientific community and the pharmaceutical sector. As research progresses, VISTA inhibitors emerge as a beacon of innovation, holding up hope not only for cancer treatments but also for viral infections, autoimmune illnesses, and other ailments.

1. VISTA: An Emerging Immune Checkpoint

1.1 Introduction to VISTA Inhibition
1.2 Structure & Biology Of VISTA Protein
1.3 Mechanism of Action of VISTA Inhibitors
1.4 VISTA Inhibition v/s Conventional Immune Checkpoints Inhibitors

2. Dual Role of VISTA as Inhibitory & Costimulatory Checkpoint

2.1 VISTA as Inhibitory Immune Checkpoint
2.2 VISTA as Costimulatory Checkpoint

3. Significance of VISTA

3.1 Role of VlSTA in Facilitating Cancer Progression
3.2 VISTA as Potential Cancer Biomarker
3.3 VISTA as Therapeutic Target in Autoimmunity

4. Global VISTA Inhibitors Market Trends & Clinical Innovation

4.1 Current Market Scenario
4.2 Future Clinical & Commercialization Opportunities

5. VISTA Targeted Therapies Trends & Clinical Innovation by Indication

5.1 Lung Cancer
5.2 Bladder Cancer
5.3 Colorectal Cancer
5.4 Hematological Cancers
5.5 Autoimmune, Inflammatory, Microbial, & Allergic Disorders

6. VISTA Targeted Therapies Trends & Clinical Innovation By Region

6.1 India
6.2 Australia
6.3 US
6.4 Europe

7. Global VISTA Inhibitors Clinical Trials Overview

7.1 By Country
7.2 By Drug Class
7.3 By Indication
7.4 By Organization
7.5 By Phase

8. Global VISTA Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase

8.1 Preclinical
8.2 Phase - I
8.3 Phase - I/II
8.4 Phase - III

9. Global VISTA Inhibitors Market Dynamics

9.1 Market Drivers & Opportunities
9.2 Market Challenges & Restraints

10. Competitive Landscape

10.1 Adimab
10.2 Aurigene Discovery Technologies
10.3 Curis
10.4 Hummingbird Bioscience
10.5 Kineta
10.6 Korea Drug Development Fund
10.7 Merck
10.8 Pierre Fabre
10.9 PharmAbcine
10.10 Sensei Biotherapeutics

简介目录图表

List of Figures

Figure 1-1: VISTA Protein - Structure
Figure 1-2: VISTA - Binding Partners
Figure 1-3: VISTA Inhibition - Basic Mechanism
Figure 1-4: VISTA Inhibition - Edge Over Conventional Checkpoint Inhibition
Figure 4-1: VISTA Inhibitors - Current Market Landscape
Figure 4-2: VISTA Inhibitor - Key Players
Figure 5-1: Pierre Fabre Laboratories - K01401-020 (W0180) Research Study
Figure 5-2: CA-170 - Clinical Trial Insights
Figure 5-3: HMBD-002 Phase I (NCT05082610) Study - Initiation & Completion Year
Figure 5-4: Lung Cancer VISTA Inhibitor - Clinical Landscape
Figure 5-5: Sensei Bio Collaborations
Figure 5-6: SNS-101 Phase I/II (NCT05864144) Study - Initiation & Completion Year
Figure 5-7: Sensei Bio Clinical Pipeline - VISTA Preclinical & Clinical Candidates
Figure 5-8: Cleveland Clinic Research Study for VISTA Inhibitors, May 2024
Figure 5-9: KVA12123 Phase I/II (NCT05708950) Study - Initiation & Completion Year
Figure 5-10: Kineta Q1 Financial Results
Figure 5-11: Aspects Influencing Global VISTA Hematological Market
Figure 5-12: Kings College London & Dartmouth College VISTA Patent

(US10745467B2) - Grant & Expiration Year

Figure 6-1: PMC-309 Phase 1 (NCT05957081) Study - Initiation & Completion Year
Figure 7-1: Global - Number Of VISTA Inhibitors In Clinical Trials By Country, 2024
Figure 7-2: Global - Number Of VISTA Inhibitors In Clinical Trials By Drug Class, 2024
Figure 7-3: Global - Number Of VISTA Inhibitors In Clinical Trials By Indication, 2024
Figure 7-4: Global - Number Of VISTA Inhibitors In Clinical Trials By Organization, 2024
Figure 7-5: Global - Number Of VISTA Inhibitors In Clinical Trials By Phase, 2024
Figure 9-1: Market Drivers & Opportunities
Figure 9-2: Market Challenges & Restraints

List of Tables

Table 5-1: Role of VISTA in Allergic, Autoimmune Disease & Viral Ailments
Table 6-1: US - Ongoing Clinical Trials for VISTA inhibitors
Table 10-1: Curis - VISTA Inhibitors Drugs Clinical Trials Insight
Table 10-2: Curis Merck & Co. - VISTA Inhibitors Drugs Clinical Trials Insight
Table 10-3: Sensei Biotherapeutics - VISTA Inhibitors Drugs Clinical Trials Insight

02-2729-4219

+886-2-2729-4219